Mar 31, 2009 - Acorda Therapeutics, Inc. announced today that the Company received a refuse to file letter from the U.S. FDA regarding its New Drug Application for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS).
The details can be read here.
No comments:
Post a Comment